LifeWave X39 patches
What studies of LifeWave X39 patches found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 3 findings, all C.
3 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: LifeWave X39 patches might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- LifeWave X39 patches · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Breathlessness1 study · 1 (few people) person received LifeWave X39 patches Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · 2010 to 2026 · since summer 2020 (few people)
Breathlessness improved.
The evidence is very uncertain about the effect of LifeWave X39 patches on breathlessness in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- since summer 2020
- Outcome
- not blue-purple or breathless
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 1 (few people) person received LifeWave X39 patches Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · 2010 to 2026 · since summer 2020 (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of LifeWave X39 patches on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- since summer 2020
- Outcome
- wore a dress reserved for swim days only
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person received LifeWave X39 patches Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · 2010 to 2026 · since summer 2020 (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of LifeWave X39 patches on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- since summer 2020
- Outcome
- brief and remarkable reprieve
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
All papers
- Home Alone 2020: A First-Person Case Study on Surviving Modern Pandemics and their Aftermath of Illnesses2026 · case report · 1 in the study
Summary
This single-person case study reports the author’s ME/CFS course from 2010 to 2026, with no comparison group and no blinding. Treatments included Valtrex (valacyclovir) eight tablets a day throughout 2016; Xue-Fu-Zhu-Yu-Tang; weekly acupuncture for eighteen months; Lomatium dissectum started in July 2019 and taken daily; Oxymatrine (or Equilibrant); X39 phototherapy patches since summer 2020; concentrated oxygen ninety minutes a day over six months; and xylitol nasal spray since winter 2020. The author reports using laboratory results and her own observations, not a validated symptom scale. After only two weeks of Chinese herbs she had a brief and remarkable reprieve. After six weeks of acupuncture she went, in her case, from being bedridden and dying to dancing; after six months of weekly acupuncture she survived a short flight and reported dancing like a twenty year old. Weekly acupuncture over eighteen months revived her, but did not kill the viruses. Lomatium produced an immediate emotional response called a pathogen “die-off” and left her feeling lighter in body and spirit. Patches restored energy; concentrated oxygen coincided with improvements in pre-diabetes, allergies, arthrosis and breathing. Valtrex viral loads never dropped, and eight tablets a day made her very ill. Harms included not tolerating certain herbs or tablets and medication overload, elimination and withdrawal; she never had the Lomatium rash. The authors state the case cannot show causation.